The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial
Open accessAbstract
Patients with high-risk endometrial carcinoma (stage IcG3, IIG3 with myometrial invasion >50%, and III) receive adjuvant therapy after surgery but it is not clear whether radiotherapy (RT) or chemotherapy (CT) is better. We randomly assigned 345 patients with high-risk endometrial carcinoma to adjuvant CT (cisplatin (50 mg m(-2)), doxorubicin (45 mg m(-2)), cyclophosphamide (600 mg m(-2)) every 28 days for five cycles, or external RT (45-50 Gy on a 5 days week(-1) schedule). The primary end points were overall and progression-free survival. After a median follow-up of 95.5 months women in the CT group as compared with the RT group, had a no significant hazard ratio (HR) for death of 0.95 (95% confidence interval (CI), 0.66-1.36; P = 0.77) and a nonsignificant HR for event of 0.88 (95% CI, 0.63-1.23; P = 0.45). The 3, 5 and 7-year overall survivals were 78, 69 and 62% in the RT group and 76, 66 and 62% in the CT group. The 3, 5 and 7-year progression-free survivals were, respectively, 69, 63 and 56 and 68, 63 and 60%. Radiotherapy delayed local relapses and CT delayed metastases but these trends did not achieve statistical significance. Overall, both treatments were well tolerated. This trial failed to show any improvement in survival of patients treated with CT or the standard adjuvant radiation therapy. Randomised trials of pelvic RT combined with adjuvant cytotoxic therapy compared with RT alone are eagerly awaited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-2 · Cited by 2,755
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Creutzberg, C. L., van Putten, W. L., Koper, P. C., Lybeert, M. L., Jobsen, J. J., Wárlám-Rodenhuis, C. C., De Winter, K. A., Lutgens, L. C., van den Bergh, A. C., van de Steen-Banasik, E., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02139-5 · Cited by 1,773
Keys, H. M., Roberts, J. A., Brunetto, V. L., Zaino, R. J., Spirtos, N. M., Bloss, J. D., Pearlman, A., Maiman, M. A., & Bell, J. G. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.11.048 · Cited by 1,671
Randall, M. E., Filiaci, V. L., Muss, H., Spirtos, N. M., Mannel, R. S., Fowler, J., Thigpen, J. T., & Benda, J. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7617 · Cited by 872
Aalders, J. G., Abeler, V. M., Kolstad, P., et al. (1980) · PubMed · Cited by 795
A note on competing risks in survival data analysis
Satagopan, J. M., Ben-Porat, L., Berwick, M., Robson, M., Kutler, D., & Auerbach, A. D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602102 · Cited by 745
Estimates of the world‐wide prevalence of cancer for 25 sites in the adult population
Pisani, P., Bray, F., & Parkin, D. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.1571 · Cited by 730
Cited by
ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002230 · Cited by 1,989
Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., & Darai, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00130-0 · Cited by 1,514
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., Gonzalez-Martin, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M. R., et al. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000609 · Cited by 767
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Oaknin, A., Bosse, T. J., Creutzberg, C. L., Giornelli, G., Harter, P., Joly, F., Lorusso, D., Marth, C., Makker, V., Mirza, M. R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.009 · Cited by 652
de Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30079-2 · Cited by 641
Self-citation
Metadata
- Authors
- Maggi, R., Lissoni, A., Spina, F., Melpignano, M., Zola, P., Favalli, G., Colombo, A., & Fossati, R.
- Venue
- British Journal of Cancer
- Published
- 2006-07-25
- Volume
- 95
- Issue
- 3
- Pages
- 266-271
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2054791534
- Cited by
- 421
- References
- 14
- FWCI
- 19.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. https://app.cochat.ai/papers/10.1038/sj.bjc.6603279
- The paper
- Maggi, R., Lissoni, A., Spina, F., Melpignano, M., Zola, P., Favalli, G., Colombo, A., & Fossati, R. (2006). Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6603279
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.